Form 4: Erasca Director Julie Hambleton Granted 120,000 Stock Options

Erasca, Inc. Director Julie Hambleton was granted 120,000 stock options with an exercise price of $1.45, vesting on June 24, 2026.

Summary

• Julie Hambleton, a Director of Erasca, Inc. (ERAS), was granted 120,000 stock options.
• The stock options have an exercise price of $1.45 per share.
• These options will vest 100% on June 24, 2026, contingent upon her continuous service to the company.
• The expiration date for these options is June 23, 2035.
• Following this transaction, Ms. Hambleton beneficially owns 120,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's interests with long-term shareholder value. It's a routine compensation event, not indicative of immediate operational performance, hence a moderately positive sentiment.

Positives

• The grant of 120,000 stock options to Director Julie Hambleton aligns her interests with those of shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 23, 2035, providing ample time for potential value realization based on future stock price appreciation.

Negatives

• The options are subject to a vesting period, with 100% vesting on June 24, 2026, meaning the benefit is not immediate and is contingent on continued service.
• The exercise price of $1.45 means the options will only have intrinsic value if Erasca's stock price rises above this level.

Risks

• The vesting of the stock options is contingent on Ms. Hambleton's continuous service to Erasca, Inc. until June 24, 2026.
• The value of the stock options is directly dependent on the future market performance of Erasca, Inc.'s common stock, specifically its ability to trade above the $1.45 exercise price.

Future Outlook

The grant of stock options to a director indicates a long-term incentive structure, aligning management's future performance with shareholder value creation, contingent on continued service.

Management Comments

• N/A This Form 4 filing reports an insider transaction and does not typically include direct management comments or quotes.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Erasca, Inc., to attract and retain talent, and to align the interests of directors with long-term shareholder value. This type of equity compensation is a standard component of corporate governance and incentive structures across publicly traded companies.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options (120,000) and exercise price ($1.45) are specific to Erasca, Inc. and its current valuation, the mechanism of using equity incentives is consistent with compensation strategies seen in comparable biotech firms such as those listed on NASDAQ, which often use stock options or restricted stock units to incentivize long-term performance and retention of key personnel.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders by incentivizing long-term stock price appreciation.
• Employees: While not directly impacting employees, such grants are part of a broader compensation philosophy that can influence overall company culture and talent retention.

Next Steps

• Monitoring the vesting of the 120,000 stock options on June 24, 2026, contingent on continuous service.
• Observing any future exercises of these options by Ms. Hambleton, which would be reported in subsequent Form 4 filings.

Key Dates

Keywords

Erasca, ERAS, stock options, director compensation, SEC Form 4, insider transaction, equity grant, executive compensation